Gelonghui, January 30丨Rendu Biotech (688193.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, the company expects to achieve net profit attributable to owners of the parent company in 2023 of 2.3 million yuan to 3.4 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will decrease by 21.03 to 19.93 million yuan, a year-on-year decrease of 90% to 85%.
Net profit attributable to owners of the parent company in 2023, after deducting non-recurring profit and loss, is expected to be -13.47 million yuan to -12.37 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will decrease by 18.41 million yuan to 17.31 million yuan, a decrease of 373% to 350% over the previous year.